Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on ropivacaine.

R D Wang1, L A Dangler, R A Greengrass

  • 1Department of Anesthesiology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.

Expert Opinion on Pharmacotherapy
|February 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Influential factors for failure of enhanced recovery after surgery from hepatectomy for hepatocellular carcinoma and the establishment of risk prediction model].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2018
Same author

Paravertebral blocks reduce the risk of postoperative urinary retention in inguinal hernia repair.

Hernia : the journal of hernias and abdominal wall surgery·2018
Same author

Metal induced self-assembly of designed V-shape protein into 2D wavy supramolecular nanostructure.

Nanoscale·2015
Same author

Paravertebral blocks for analgesia following BM harvest.

Bone marrow transplantation·2011
Same author

Three-dimensional ultrasound-assisted popliteal catheter placement revealing aberrant anatomy: implications for block failure.

Acta anaesthesiologica Scandinavica·2008
Same author

[Protective effect of ONO-1078, a leukotriene antagonist, on focal cerebral ischemia in mice].

Yao xue xue bao = Acta pharmaceutica Sinica·2003
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Ropivacaine, a long-acting local anesthetic, offers improved cardiovascular safety and a wider margin of safety compared to bupivacaine. It provides differential sensory and motor block, with a lower risk of cardiotoxicity from accidental injection.

Area of Science:

  • Anesthesiology
  • Pharmacology

Background:

  • Long-acting local anesthetics are crucial for regional anesthesia and analgesia.
  • Bupivacaine has been a standard, but concerns exist regarding its cardiovascular safety.
  • Ropivacaine emerged as a newer agent with potential safety and efficacy advantages.

Purpose of the Study:

  • To compare the cardiovascular safety and efficacy of ropivacaine with bupivacaine.
  • To evaluate the differential sensory and motor block characteristics of ropivacaine.
  • To assess the risk of cardiotoxicity associated with ropivacaine in clinical practice.

Main Methods:

  • Review of post-marketing studies comparing bupivacaine and ropivacaine.
  • Analysis of animal toxicity studies on myocardial depression and arrhythmogenic potential.

Related Experiment Videos

  • Literature review on cardiotoxicity risks following inadvertent intravascular injection.

    • Main Results:

    • Ropivacaine demonstrates increased cardiovascular safety and a wider margin of safety than bupivacaine at equal doses.
    • Ropivacaine offers a greater differential sensory-motor block and a shorter elimination half-life, reducing accumulation potential.
    • Animal studies confirm ropivacaine's reduced cardiotoxicity, including less myocardial depression and lower arrhythmogenic potential.

    Conclusions:

    • Ropivacaine presents a favorable safety profile, particularly regarding cardiovascular toxicity, compared to bupivacaine.
    • Its distinct characteristics, including reduced cardiotoxicity, make it a safer option for regional anesthesia.
    • Ongoing studies are evaluating ropivacaine against levobupivacaine, another long-acting local anesthetic.